Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia gravis is a rare, chronic autoimmune disorder that causes serious muscle weakness.

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis ...

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis Global MG Community turns Awareness into Action to ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

The Phase 3 AURORA trial tests Descartes-08 against a placebo in patients with acetylcholine receptor autoantibody positive myasthenia gravis. How many participants are enrolled in the AURORA trial?

Myasthenia gravis is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fluctuating muscle weakness and fatigue in symptoms, long treatment cycles ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Neurology of Central Florida Dr. Alicia Cabrera is an adult neurologist with over 25 years of experience in the field. She’s ...